跳到正文
cccskills
免费在 GitHub 公开

endo-assess-infusion-site-health

This skill evaluates infusion site health and rotates sites appropriately to prevent lipohypertrophy or infection. It is triggered when clinicians inspect pump sites for irritation or lumps or review site rotation practice at visit.

中文简介正在准备中。当前显示原文说明。

实测评分 未实测

查看安装方法

包含的文件(1)

  • SKILL.md2.1 KB

SKILL.md(原文)

安装前可以查看交给 AI 代理的指令内容。

Assess infusion site health and selection

STEP 1 — Gather Information

Inspect the infusion site for erythema, induration, lumps, lipohypertrophy, signs of infection (purulence, warmth, pain), and assess site rotation pattern (frequency, areas used). Ask patient about discomfort or difficulty with insertion.

STEP 2 — Rule In / Rule Out

Determine if the infusion site shows any signs of lipohypertrophy, infection, or significant irritation.

STEP 3 — Classify or Stratify

Classify the site as healthy, mild irritation, lipohypertrophy, or infection based on findings.

STEP 4 — Decide

If healthy, continue use and reinforce rotation schedule; if unhealthy, discontinue the set, treat infection if present, select a new site at least 2 cm from the previous site, and educate the patient on proper rotation and site inspection.

Clinical Guardrails / Mimics / Pitfalls

Do not reuse sites with visible lipohypertrophy or induration; do not ignore patient‑reported pain; avoid rotating only within the same anatomical quadrant; do not insert into scar tissue or areas of prior infection without full healing; do not rely solely on patient self‑report without visual inspection.

Concrete Clinical Example

A 28‑year‑old with T1DM reports tenderness at the left abdominal infusion site. Inspection reveals a 1‑cm firm lump consistent with lipohypertrophy. The site is classified as unhealthy; the infusion set is moved to the right abdomen, the patient is taught to rotate sites every 2–3 days and to inspect each new site before insertion.

Source: Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI: 10.1210/jc.2016-2534

评价

还没有评价。欢迎分享你的使用感受。

评论

无需登录即可发表。欢迎分享使用感受、提问,或说明在哪些环境下无法运行。

还没有评论。来写第一条吧。

提交后会立即公开。请勿填写邮箱、电话等个人信息。URL 最多 2 个。

0 / 1000 字

此表单受 reCAPTCHA 保护,适用 Google 的隐私权政策和服务条款。

同一仓库的技能

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

查看 dromlakhani 的全部技能

报告此技能的问题